Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) (SPI2)

What is the purpose of this trial?

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

Participation Guidelines

Ages: 18 - 65 years

Gender: Both

MedDay Pharmaceuticals SA

Start Date: 04/21/2017

End Date: 08/31/2018

Last Updated: 02/22/2018

Study HIC#: 2000020124

Get Involved

For more information about this study, contact:
Sharon Stoll

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Sharon Stoll

Principal Investigator